A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer

A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer

Therapeutic targeting of advanced or metastatic non-small-cell lung cancer (NSCLC) represents a major goal of clinical treatment. Polo-like kinase 1 (PLK1) is an essential mitotic kinase in cell cycle progression and is associated with oncogenesis in a large spectrum of cancer types, including NSCLC...

Full description

Bibliographic Details
Main Authors: Lifeng Li, Wenhua Xue, Zhibo Shen, Jie Liu, Min Hu, Zhenyong Cheng, Yuxing Wang, Yulu Chen, Hao Chang, Yingyi Liu, Bin Liu, Jie Zhao
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:Molecular Therapy: Oncolytics
Subjects:
immunomodulatory drugs
IMiDs
CC-885
PLK1
volasertib
NSCLC
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770520300929

Similar Items

Similar Items